Inherent Biosciences announced a comprehensive commercial partnership agreement with Genomic Prediction. This collaboration is set to advance male reproductive health by integrating Inherent Biosciences’ groundbreaking Epigenetic Sperm Quality Test (SpermQT™ marketed under the brand Path Fertility) into Genomic Prediction’s suite of clinical laboratory tests.